An update on adenomyosis uteri  by Hong, Sze Ching & Khoo, Chong Kiat
lable at ScienceDirect
Gynecology and Minimally Invasive Therapy 5 (2016) 106e108Contents lists avaiGynecology and Minimally Invasive Therapy
journal homepage: www.e-gmit .comReview articleAn update on adenomyosis uteri
Sze Ching Hong*, Chong Kiat Khoo
Minimally Invasive Surgery Unit, Division of Obstetrics and Gynaecology, KK Women's and Children's Hospital, Singapore, Singaporea r t i c l e i n f o
Article history:
Received 10 March 2014
Received in revised form
25 May 2015
Accepted 20 August 2015
Available online 1 September 2015
Keywords:
adenomyosis
endometrial hyperplasia
endometriosis
hysterectomy
leiomyomasConﬂicts of interest: The authors have no conﬂict
article.
* Corresponding author. 100 Bukit Timah Road, Sin
E-mail address: hong.sze.ching@singhealth.com.sg
http://dx.doi.org/10.1016/j.gmit.2015.08.003
2213-3070/Copyright©2015, TheAsia-PaciﬁcAssociation fo
BY-NC-ND license (http://creativecommons.org/licenses/by-a b s t r a c t
Adenomyosis is a gynecological condition commonly encountered in clinical practice. It is deﬁned as the
presence of endometrium within the myometrium. The prevalence of this condition in asymptomatic
women is unclear, and a large proportion of these women may have associated pathology such as
leiomyomas, endometriosis, endometrial polyps, and hyperplasia. Most of the time, diagnosis is made on
histological examination of specimen following hysterectomy or adenomyomectomy. We will look at the
role of various imaging modalities, such as pelvic ultrasound and magnetic resonance imaging, and their
value in improving the accuracy of preoperative diagnosis. Various medical and surgical therapies will
also be discussed. Careful counseling on the available treatment options form an important component of
clinical care. Hysterectomy is the deﬁnitive treatment for women who no longer desire fertility.
Copyright © 2015, The Asia-Paciﬁc Association for Gynecologic Endoscopy and Minimally Invasive
Therapy. Published by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Introduction
Adenomyosis is a gynecological condition commonly encoun-
tered in our clinical practice. It is deﬁned as the presence of
endometrial glands and stroma deep within the myometrium
associated with myometrial hypertrophy and hyperplasia.1 General
consensus is that adenomyosis occurs when there is a disruption of
the normal boundary between the endometrial basal layer and the
myometrium. As a result, the endometrial glands invade the myo-
metrium, resulting in ectopic intramyometrial glands, which cause
adjacent myometrial hypertrophy and hyperplasia. Adenomyosis
can be diffuse, where islands of adenomyosis may be found
throughout the myometrium, or it can be localized in the form of
adenomyomas.Epidemiology
The exact prevalence of this condition in asymptomatic women
is unclear, and the reported prevalence in surgical series varies
widely due to the differences in histological diagnostic criteria used
and number of tissue sections analyzed. Estimated prevalence ofs of interest relevant to this
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nc-nd/4.0/).histologically conﬁrmed adenomyosis in surgical series ranges from
5% to 70%.2 A large proportion of these womenmay have associated
pathology such as leiomyomas (80%), endometriosis (6.3e24%),
endometrial polyps (2.3e14.7%), endometrial hyperplasia
(3.5e13.6%), and adenocarcinoma (2.2e5.3%).3 Adenomyosis is
most common in women aged 35e50 years, and many cases occur
in multiparous women.Pathogenesis
The exact cause and pathogenesis of adenomyosis has not been
well established. One theory states that adenomyosis originates
from the basalis (deeper layer) of the endometrium, which grows
between the smoothmuscle bundles in themyometrium due to the
action of speciﬁc enzymes. This repeated process of regeneration
and re-epithelization leads to a loss of the interface between the
endometrium and myometrium and there is myometrial hyper-
trophy around the foci of endometrium. The reason for this is un-
clear, however, it may involve the invaginating endometrium
pushing aside the smoothmuscle bundles or the body’s response to
control this invagination. Other factors also contribute to the
pathogenesis, namely hormonal, genetic, and immunological fac-
tors.4,5 Hyperestrogenism at the local level in addition to circulating
estrogens may be another contributing factor. Adenomyosis grows
and regress in an estrogen-dependent fashion due to the presence
of estrogen receptors in adenomyotic tissues.6ly InvasiveTherapy. PublishedbyElsevier TaiwanLLC. This is anopenaccessarticleunder theCC
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Some patients may be asymptomatic, where it is an incidental
ﬁnding on examination, imaging studies, or histopathology speci-
mens, after hysterectomies. Others can have menorrhagia
(40e50%) or metrorrhagia (10e12%), dysmenorrhea (30%), dys-
pareunia, chronic pelvic pain, or abdominal bloating.7 The fre-
quency and severity of symptoms correlate to the extent and depth
of adenomyosis. Physical examinationmay reveal a tender enlarged
uterus.8Work-up
At present there is no single diagnostic test that is both sensitive
and speciﬁc for adenomyosis. There is a lack of a reliable and
diagnostic test for this condition at present, even though diagnosis
is important in order to decide on the appropriate mode of man-
agement for the patient, and would greatly impact on patient
counseling.Pelvic ultrasound
Transvaginal ultrasound (TVS) is superior to transabdominal
ultrasound in evaluating features of adenomyosis uteri. Sono-
graphic appearances include uterine enlargement, asymmetric
enlargement of the anterior or posterior myometrial wall, lack of
contour abnormality or mass effects, heterogeneous, poorly cir-
cumscribed areas within the myometrium, hyperechoic islands or
nodules, ﬁnger-like projections or linear striations, indistinct
endometrial stripe, and anechoic lacunae or cysts of varying sizes.
The accuracy of TVS reported in studies on the accuracy indices of
sensitivity and speciﬁcity ranges between 53e89% and 50e99%.9
There are some reports10 on the use of three-dimensional TVS
and three-dimensional power Doppler studies in adenomyosis,
looking at vessel distribution and branching, and differences in
perfusion patterns in affected areas.Hysterosalpingography
Hysterosalpingography has a low sensitivity and speciﬁcity for
the diagnosis of adenomyosis. Features include multiple small
spicules extending from the endometrium into the myometrium
and local accumulation of contrast in the myometrium giving a
honeycomb appearance.11Magnetic resonance imaging
Magnetic resonance imaging (MRI) features of adenomyosis
include a focal or diffuse thickened junctional zone due to unco-
ordinated proliferation of the inner myometrial cells causing
junctional zone hyperplasia. Areas of low signal intensities repre-
senting smooth muscle hyperplasia and foci of increased high
signal intensity in the junctional zone representing heterotopic
endometrial tissue can be seen on MRI.12
MRI as an imaging modality for adenomyosis has been
compared with transvaginal ultrasound. Some studies found that
both modalities have similar sensitivities and speciﬁcities, whereas
others showed that MRI was a good complement to ultrasound
when ultrasound is indeﬁnite or in difﬁcult cases with presence of
other abnormalities (such as leiomyomas and endometriosis). In
such situations, MRI may add more information and increase the
diagnostic accuracy.12Treatment options
Increasingly, the diagnosis of adenomyosis is being made before
surgery due to the improvement in imaging modalities and this
gives women with this condition the option of medical therapy.
However, because of the diagnostic challenges of adenomyosis,
there are not many large or well-designed trials that look at the
treatment of this disease itself. Many treatment options are aimed
at symptomatic relief, with hysterectomy being the main treatment
option for those who have completed their families.Medical
Nonhormonal treatments are targeted at symptomatic relief.
Nonsteroidal anti-inﬂammatory drugs such as mefenamic acid are
effective for relief of symptoms such as dysmenorrhea and heavy
menstrual bleeding. Tranexamic acid, which is an antiﬁbrinolytic, is
used in cases of menorrhagia.
Hormonal treatment is aimed at inhibiting gonadotrophin
release from the pituitary, estrogen surge midcycle and cyclical
changes of ovarian steroids. However, the effects of these
treatments are variable and tend to wear off after discontinuation
of treatment, leading to symptom recurrence. Progestogens,
levonorgestrel (LNG) intrauterine system, oral contraceptive pills,
gonadotrophin-releasing hormone analogs, and danazol-loaded
intrauterine devices (IUDs) are the different types of hormonal
treatment available.
Progestogens and oral contraceptive pills have limited effec-
tiveness as adenomyosis is largely an estrogen-mediated disease,
but may be effective in symptomatic relief of menorrhagia and
dysmenorrhea.
LNG-IUD use in women with adenomyosis results in less men-
strual blood loss, reduction in uterine size, and improvement in
dysmenorrhea.13 The main disadvantage of this treatment is the
irregular menstrual bleeding in the ﬁrst few months of treatment.
Gonadotrophin-releasing hormone analogs induce medical
menopause and leads to atrophy of adenomyotic nodules resulting
in reduction of uterine size and symptomatic relief. Its use is limited
to short term (3e6 months) because of its menopausal and skeletal
side effects. Once the treatment is discontinued, the condition
recurs.
Oral danazol is no longer commonly used because of its side
effects. Danazol-loaded IUDs have been shown in some studies to
improve symptoms such as dysmenorrhea and hypermenorrhea.
Serum danazol levels were undetectable and the patients did not
experience the systemic side effects associated with oral
danazol.14,15Surgical
Hysterectomy has been the deﬁnitive treatment for adeno-
myosis as well as for deﬁnite diagnosis until recently.16 However,
this option is only for patients who have completed their families.17
Excision of affected myometrium can be performed in patients
where the extent of disease is well-deﬁned. This is a viable option in
patients who still desire fertility. However, in cases where large or
multiple areas of the uterus is affected, there is a risk of future
obstetric complications such as uterine rupture, and risk of adhe-
sion formation. Endomyometrial ablation or resection is an option
for patients with superﬁcial disease, however, deep-seated disease
is associated with a risk of failure of treatment. Desire for future
fertility is a contraindication. Uterine artery embolization is an
option in patients with concurrent ﬁbroids for which it is an
accepted treatment. Laparoscopic uterine artery ligation has not
S.C. Hong, C.K. Khoo / Gynecology and Minimally Invasive Therapy 5 (2016) 106e108108been well studied and available studies have not shown it to be
effective.9
Conclusion
Adenomyosis is a common condition encountered by gynecolo-
gists. Its symptomology is poorly deﬁned and severity of symptoms
sometimes correlates poorly with severity of disease. The etiology of
the disease is unclear and the exact prevalence of this condition in
asymptomatic women is not known. Advancement in imaging mo-
dalities such as MRI can help to establish the diagnosis of adeno-
myosismore accurately and thiswill lead to better patient counseling
before surgery and more directed treatment. Hormonal treatment
can relieve symptoms and reduce the progression of the disease, but
is limited by the side effects. Long-term studies regarding the
effectiveness of hormonal treatment as well as long-term outcomes
such as fertility and pregnancy are awaited. Hysterectomy and LNG
intrauterine system is still the cornerstone of treatment.
References
1. Vercellini P, Vigano P, Somigliana E, Daguati R, Abbiati A, Fedele L. Adeno-
myosis: epidemiological factors. Best Pract Res Clin Obstet Gynaecol. 2006;20:
465e477.
2. Azziz R. Adenomyosis: current perspectives. Obstet Gynecol Clin North Am.
1989;16:221e235.
3. Bergholt T, Eriksen L, Berendt N, Jacobsen M, Hertz JB. Prevalence and risk
factors of adenomyosis at hysterectomy. Hum Reprod. 2001;16:2418e2421.
4. Yen CF, Wang HS, Lee CL, Liao SK. Roles of integrin-linked kinase in cell
signaling and its perspectives as a therapeutic target. Gynecol Minim Invas Ther.
2014;3:67e71.5. Abe W, Nasu K, Tsuno A, Kawano Y, Narahara H. Phosphatidylinositol-3 kinase-
Akt-mammalian target of rapamycin signaling pathway mediates contractility
of human endometriotic stromal cells: a promising new target for the treat-
ment of endometriosis-associated ﬁbrosis. Gynecol Minim Invas Ther. 2014;3:
115e118.
6. Kitawaki J. Adenomyosis: the pathophysiology of an oestrogen-dependent
disease. Best Pract Res Clin Obstet Gynaecol. 2006;20:493e502.
7. Bergeron C, Amant F, Ferenczy A. Pathology and physiopathology of adeno-
myosis. Best Pract Res Clin Obstet Gynaecol. 2006;20:511e521.
8. Peric H, Fraser IS. The symptomatology of adenomyosis. Best Pract Res Clin
Obstet Gynaecol. 2006;20:547e555.
9. Mehasseb MK, Habiba MA. Adenomyosis uteri: an update. Obstet Gynaecol.
2009;11:41e47.
10. Sharma K, Bora MK, Venkatesh B, et al. Role of 3D ultrasound and Doppler in
differentiating clinically suspected cases of leiomyoma and adenomyosis of
uterus. J Clin Diagn Res. 2015;9(4):QC08eQC12. http://dx.doi.org/10.7860/
JCDR/2015/12240.5846.
11. Wolf DM, Spataro RF. The current state of hysterosalpingography. Radio-
graphics. 1988;8:1041e1058.
12. Dueholm M, Lundorf E, Sørensen JS, Ledertoug S, Olesen F, Laursen H. Repro-
ducibility of evaluation of the uterus by transvaginal sonography, hyster-
osonographic examination, hysteroscopy and magnetic resonance imaging.
Hum Reprod. 2002;17:195e200.
13. Farquhar C, Brosens I. Medical and surgical management of adenomyosis. Best
Pract Res Clin Obstet Gynaecol. 2006;20:603e616.
14. Igarashi M, Abe Y, Fukuda M, Ando A, Miyasaka M, Yoshida M. Novel conser-
vative medical therapy for uterine adenomyosis with a danazol-loaded intra-
uterine device. Fertil Steril. 2000;74:412e413.
15. Liu X, Yu S, Guo SW. A pilot study on the use of andrographolide to treat
symptomatic adenomyosis. Gynecol Minim Invasive Ther. 2014;3:119e126.
16. Wong FWS, Lim DCE. Factors inﬂuencing the choice of hysterectomy approach
for the management of ﬁbroid uterus. Gynecol Minim Invasive Ther. 2013;2:
61e64.
17. Herrmann A, DeWilde RL. Laparoscopic myomectomydthe gold standard.
Gynecol Minim Invasive Ther. 2014;3:31e38.
